$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

$aldx Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000119312516767770 Filed on November 14, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.210M	$1.400M	$1.260M
YoY Change	-1.63%	11.11%	63.64%
% of Gross Profit
Research & Development	$3.450M	$3.380M	$2.076M
YoY Change	10.93%	62.77%	73.66%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%
% of Gross Profit
Operating Expenses	$4.650M	$3.380M	$2.076M
YoY Change	7.14%	62.77%	73.66%
Operating Profit		-$4.776M	-$3.338M
YoY Change		43.11%	69.58%
Interest Expense	$0.00	$26.65K	$28.08K
YoY Change	-100.0%	-5.08%	-31.63%
% of Operating Profit
Other Income/Expense, Net		$1.138K	-$28.08K
YoY Change		-104.05%	-31.63%
Pretax Income	-$4.650M	-$4.780M	-$3.370M
YoY Change	6.65%	41.84%	67.66%
Income Tax
% Of Pretax Income
Net Earnings	-$4.650M	-$4.775M	-$3.366M
YoY Change	6.65%	41.88%	67.51%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.35
Diluted Earnings Per Share	-$369.6K	-$383.3K	-$0.35
COMMON SHARES
Basic Shares Outstanding	12.58M shares	12.47M shares	9.713M shares
Diluted Shares Outstanding			9.713M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.90M	$28.90M	$30.60M
YoY Change	-9.78%	-5.56%	202.97%
Cash & Equivalents	$12.02M	$14.57M	$30.62M
Short-Term Investments	$12.90M	$14.30M
Other Short-Term Assets	$200.0K	$300.0K	$600.0K
YoY Change	-60.0%	-50.0%	200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$25.13M	$29.13M	$31.23M
YoY Change	-10.53%	-6.72%	201.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.35K	$65.69K	$88.46K
YoY Change	-29.85%	-25.74%	1433.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$56.35K	$65.69K	$124.7K
YoY Change	-51.66%	-47.32%	2061.91%
TOTAL ASSETS
Total Short-Term Assets	$25.13M	$29.13M	$31.23M
Total Long-Term Assets	$56.35K	$65.69K	$124.7K
Total Assets	$25.19M	$29.19M	$31.35M
YoY Change	-10.7%	-6.89%	202.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$275.4K	$733.6K	$743.6K
YoY Change	-67.64%	-1.35%	54.13%
Accrued Expenses	$1.946M	$1.477M	$630.3K
YoY Change	64.04%	134.26%	73.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$77.55K	$426.5K	$0.00
YoY Change	0.0%
Total Short-Term Liabilities	$2.299M	$2.637M	$1.374M
YoY Change	8.7%	91.9%	62.38%
LONG-TERM LIABILITIES
Long-Term Debt	$1.239M	$883.3K	$1.281M
YoY Change	2.25%	-31.05%	3.24%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.239M	$883.3K	$1.281M
YoY Change	2.25%	-31.05%	3.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.299M	$2.637M	$1.374M
Total Long-Term Liabilities	$1.239M	$883.3K	$1.281M
Total Liabilities	$3.538M	$3.520M	$2.655M
YoY Change	6.36%	32.58%	27.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$77.30M	-$72.65M	-$54.25M
YoY Change	31.91%	33.93%	23.1%
Common Stock	$98.95M	$98.31M	$82.94M
YoY Change	18.52%	18.54%	1490311.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.65M	$25.67M	$28.70M
YoY Change
Total Liabilities & Shareholders Equity	$25.19M	$29.19M	$31.35M
YoY Change	-10.7%	-6.89%	202.89%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$4.650M	-$4.775M	-$3.366M
YoY Change	6.65%	41.88%	67.51%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$3.910M	-$3.510M	-$2.880M
YoY Change	31.21%	21.88%	138.02%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$60.00K
YoY Change		-100.0%	500.0%
Acquisitions
YoY Change
Other Investing Activities	$1.320M	$570.0K
YoY Change	-110.19%
Cash From Investing Activities	$1.320M	$560.0K	-$60.00K
YoY Change	-110.19%	-1033.33%	500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	40.00K	-100.0K	-10.00K
YoY Change	-200.0%	900.0%	-94.12%
NET CHANGE
Cash From Operating Activities	-3.910M	-3.510M	-2.880M
Cash From Investing Activities	1.320M	560.0K	-60.00K
Cash From Financing Activities	40.00K	-100.0K	-10.00K
Net Change In Cash	-2.550M	-3.050M	-2.950M
YoY Change	-84.03%	3.39%	112.23%
FREE CASH FLOW
Cash From Operating Activities	-$3.910M	-$3.510M	-$2.880M
Capital Expenditures	$0.00	$0.00	-$60.00K
Free Cash Flow	-$3.910M	-$3.510M	-$2.820M
YoY Change	31.21%	24.47%	135.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12576326	shares
CY2015Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0
CY2015Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	36236
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30618365
CY2015Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.35
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	802921	shares
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3701212
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	957328
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	28450968
CY2016Q3	us-gaap	Cash Cash	424613
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12568563	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12568563	shares
CY2016Q3	us-gaap	Assets Assets	29191477
CY2016Q3	us-gaap	Assets Current AssetsCurrent	29125787
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	98302346
CY2016Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	14307073
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14568508
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	12569
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	733560
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6528
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	28400545
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1476592
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	883282
CY2016Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	426505
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Liabilities Liabilities	3519939
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29191477
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2636657
CY2016Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	43895
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5211390
CY2016Q3	us-gaap	Share Price SharePrice	7.82
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65690
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.21
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	25671538
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.76
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	759251	shares
CY2016Q3	us-gaap	Securities For Reverse Repurchase Agreements SecuritiesForReverseRepurchaseAgreements	14100000
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72649905
CY2016Q3	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	14300545
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	250206
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3195987
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1604871	shares
CY2016Q3	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	415060
CY2016Q3	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	104204
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8527304
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.50
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1100000	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.00
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.50
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	211528	shares
CY2015Q1	us-gaap	Share Price SharePrice	20.00
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1211310
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	77546
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Liabilities Liabilities	3326445
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28204764
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.33
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	394773
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	25927662
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9712521	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9712521	shares
CY2015Q4	us-gaap	Assets Assets	28204764
CY2015Q4	us-gaap	Assets Current AssetsCurrent	28088194
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83478851
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	12941776
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14648866
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	9713
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	851160
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8361
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1186429
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2115135
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	48657
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80334
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	24878319
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.98
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58601884
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	497552
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1077330	shares
CY2015Q4	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	550323
CY2015Q4	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	192676
CY2015Q4	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	36236
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12600000
CY2016Q2	us-gaap	Sale Of Stock Transaction Date SaleOfStockTransactionDate	2016-06-01
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1100000	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7100000
CY2015Q1	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	0.125
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	211528	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1900000
CY2015Q1	aldx	Redemption Price Of Warrants RedemptionPriceOfWarrants	0.001
CY2015Q1	aldx	Average Trading Volume Of Common Stock AverageTradingVolumeOfCommonStock	50000	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	28061
CY2015Q1	aldx	Expiration Of Warrant ExpirationOfWarrant	P3Y
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2423138	shares
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22091061
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1639930
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3188176
	us-gaap	Depreciation Depreciation	10649
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7734431
	us-gaap	Interest Paid InterestPaid	55775
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-84314
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-278401
	us-gaap	Net Income Loss NetIncomeLoss	-7734431
	us-gaap	Interest Expense InterestExpense	84314
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-86119
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	402329
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	374767
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7650117
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	28483810
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6306630
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86119
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28505808
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4461941
	us-gaap	Share Based Compensation ShareBasedCompensation	1639930
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8270405	shares
	aldx	Deferred Offering Costs Paid By Cash DeferredOfferingCostsPaidByCash	21998
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-182963
	dei	Entity Registrant Name EntityRegistrantName	ALDEYRA THERAPEUTICS, INC.
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20931
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3016545	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001341235
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>2.</b></td> <td valign="top" align="left"><b>BASIS OF PRESENTATION</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The accompanying interim unaudited condensed financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s financial statements and related footnotes for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on March 30, 2016. The financial information as of September 30, 2016, the three and nine months ended September 30, 2016 and 2015 is unaudited, but in the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of the financial position, results of operations and cash flows at the dates and for the periods presented of the results of these interim periods have been included. The balance sheet data as of December 31, 2015 was derived from audited financial statements. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> On June 1, 2016, the Company closed an underwritten public offering in which it sold, an aggregate of approximately 2.8 million shares of common stock, including 360,000 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The net proceeds of the offering, including the full exercise of the option, were approximately $12.6 million, after deducting the underwriting discounts and commissions and the other offering expenses payable by Aldeyra.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The Company’s management believes that its currently available resources, including amounts potentially available under its credit facility (Note 7), will provide sufficient funds to enable the Company to meet its expected obligations through approximately the second quarter of 2018 based on the Company’s current business plan. However, these amounts will not be sufficient for the Company to commercialize its product candidates or conduct any substantial, additional development requirements requested by the U.S. Food and Drug Administration (FDA). Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, or meet financial covenants that could be implemented under the Company’s term loans in certain circumstances, it will be required to significantly decrease the amount of planned expenditures, and may be required to cease operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Curtailment of operations would cause significant delays in the Company’s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b><i>Recent Accounting Pronouncements</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) <font style="WHITE-SPACE: nowrap">No. 2016-15</font> <font style="WHITE-SPACE: nowrap">(ASU 2016-15),</font> Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The standard is intended to reduce the diversity in practice around how certain transactions are classified within the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. <font style="WHITE-SPACE: nowrap">ASU 2016-15</font> may be adopted retrospectively or prospectively if it is impractical to apply the amendments retrospectively. The Company does not expect this standard to have a material impact on its financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In April 2016 and May 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No. 2016-10</font> <font style="WHITE-SPACE: nowrap">(ASU 2016-10),</font> Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations & Licensing which provides further clarification for the implementing the new revenue recognition standard, ASU 2014-09. The effective date and transition requirements for <font style="WHITE-SPACE: nowrap">ASU 2016-10</font> are the same as the effective date of ASU <font style="WHITE-SPACE: nowrap">2014-09. The</font> Company does not expect this standard to have a material impact on its financial statements.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In March 2016, the FASB issued ASU No. 2016-09 “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), to simplify the accounting for stock compensation. This update focuses on income tax accounting, award classification, estimating forfeitures, and cash flow presentation. The ASU becomes effective in 2017 for public companies and in 2018 for all other entities. Early adoption is permitted. Certain disclosures and detailed transition provisions apply. The Company does not believe that ASU 2016-09 will have a material impact on its financial statements.</p> </div>
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-80358
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.28
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2159714
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4314483
	us-gaap	Depreciation Depreciation	26454
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14033132
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Interest Paid InterestPaid	58722
	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	58160
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5044
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	290163
	us-gaap	Net Income Loss NetIncomeLoss	-14048021
	us-gaap	Interest Expense InterestExpense	79507
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1545181
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-117600
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-247346
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14889
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14042977
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	15378371
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12702873
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	14889
	us-gaap	Investment Income Interest InvestmentIncomeInterest	74463
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra), a Delaware corporation, is developing new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to naturally occurring toxic and pro-inflammatory chemical species known as aldehydes.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The Company’s principal activities to date include raising capital and research and development activities.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11238050
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11810
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12702873
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	96042	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M5D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.35
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3M18D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.68
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.55
	aldx	Number Of Incentive Plans NumberOfIncentivePlans	3	Incentive_Plan
	dei	Trading Symbol TradingSymbol	ALDX
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9728494
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	721814	shares
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13845000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	36157	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	2159714
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10942127	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
	aldx	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00	pure
	aldx	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice	4.83
	aldx	Interest Payment Period For Line Of Credit Facility InterestPaymentPeriodForLineOfCreditFacility	November 2013 through November 2014
	aldx	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	62104	shares
	aldx	Line Of Credit Facility Maturity Month And Year LineOfCreditFacilityMaturityMonthAndYear	2016-11
CY2015Q4	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0650	pure
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2423138	shares
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	536269
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1261196
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3365687
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28081
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-3365687
CY2015Q3	us-gaap	Interest Expense InterestExpense	28081
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3337606
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2076410
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9712521	shares
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3016545	shares
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	877025
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1396734
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4773482
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1138
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-4775307
CY2016Q3	us-gaap	Interest Expense InterestExpense	26654
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1825
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4776445
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1825
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	27792
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3379711
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12474609	shares

Files In Submission

Name	View Source	Status
0001193125-16-767770-index-headers.html	Edgar Link	pending
0001193125-16-767770-index.html	Edgar Link	pending
0001193125-16-767770.txt	Edgar Link	pending
0001193125-16-767770-xbrl.zip	Edgar Link	pending
aldx-20160930.xml	Edgar Link	completed
aldx-20160930.xsd	Edgar Link	pending
aldx-20160930_cal.xml	Edgar Link	unprocessable
aldx-20160930_def.xml	Edgar Link	unprocessable
aldx-20160930_lab.xml	Edgar Link	unprocessable
aldx-20160930_pre.xml	Edgar Link	unprocessable
d271002d10q.htm	Edgar Link	pending
d271002dex311.htm	Edgar Link	pending
d271002dex312.htm	Edgar Link	pending
d271002dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

2016 Q4 Form 10-Q Financial Statement

#000119312516767770 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX Aldeyra Therapeutics, Inc. Stock $aldx

2016 Q4 Form 10-Q Financial Statement

#000119312516767770 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx